These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 1982079)

  • 21. [Behavioral assessment of neuroleptics (2)--stereotypy].
    Koshikawa N
    Yakubutsu Seishin Kodo; 1992 Feb; 12(1):1-7. PubMed ID: 1357840
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pole-climbing performance of rats under neuroleptics.
    Kazdová E; Dlabac A
    Act Nerv Super (Praha); 1977 Jul; 19 Suppl 2():336-7. PubMed ID: 45165
    [No Abstract]   [Full Text] [Related]  

  • 23. Morphine potentiates the impairing effects of neuroleptics on two-way active conditioned avoidance response in male mice.
    Aguilar MA; Miñarro J; Simón VM
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):225-37. PubMed ID: 14751417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of psychotropic drugs on the central dopamine metabolism (example: neuroleptics)].
    Havemann U
    Arzneimittelforschung; 1981; Suppl 27():18-22. PubMed ID: 6118158
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The influence of systemically administered selective dopamine antagonists of D1 and D2/D3 types on alimentary and escape conditioned placing reactions in cats].
    Zh Vyssh Nerv Deiat Im I P Pavlova; 2004; 54(4):489-94. PubMed ID: 15481386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
    Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
    Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropsychopharmacological profile of remoxipride in comparison with clozapine.
    Skuza G; Rogóz Z; Wieczorek A
    Pol J Pharmacol; 1997; 49(1):5-15. PubMed ID: 9431546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative characteristics of neuroleptics as antagonists of noradrenaline and dopamine].
    Abramets II; Arnol'dova KA; Dolzhenko AT; Komissarov IV
    Farmakol Toksikol; 1981; 44(3):287-91. PubMed ID: 6116613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.
    Nohria V
    Methods Find Exp Clin Pharmacol; 1983; 5(6):357-64. PubMed ID: 6137599
    [No Abstract]   [Full Text] [Related]  

  • 33. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sex differences in the effects of neuroleptics on escape-avoidance behavior in mice: a review.
    Parra A; Arenas MC; Monleón S; Vinader-Caerols C; Simón VM
    Pharmacol Biochem Behav; 1999 Dec; 64(4):813-20. PubMed ID: 10593205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A study of inhibition of cholera toxin-induced intestinal hypersecretion by neuroleptics.
    Larsen JJ
    Acta Pharmacol Toxicol (Copenh); 1982 Apr; 50(4):294-9. PubMed ID: 6125081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic effects on acquisition and performance of learned behaviors: a reinterpretation.
    Servan-Schreiber D; Blackburn JR
    Life Sci; 1995; 56(25):2239-45. PubMed ID: 7791511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of neuroleptics on cognition and diagnosis, and their influence on stereotypies.
    Campbell M
    J Ment Defic Res; 1987 Jun; 31 ( Pt 2)():220-5. PubMed ID: 2887661
    [No Abstract]   [Full Text] [Related]  

  • 38. The effect of 2-substitution on conformations and brain concentrations of phenothiazine-neuroleptics in relation to dopamine-antagonism.
    Grol CJ; Rollema H; Asselbergs HW
    J Pharm Pharmacol; 1979 Oct; 31(10):667-71. PubMed ID: 41038
    [No Abstract]   [Full Text] [Related]  

  • 39. Changes in body temperature after administration of amino acids, peptides, dopamine, neuroleptics and related agents.
    Clark WG
    Neurosci Biobehav Rev; 1979; 3(4):179-231. PubMed ID: 44354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A series of hexahydro[1,4]oxazino[3,4-a]isoquinolines as potential neuroleptics.
    Clarke FH; Hill RT; Koo J; Lopano RM; Maseda MA; Smith M; Soled S; VonVeh G; Vlattas I
    J Med Chem; 1978 Aug; 21(8):785-91. PubMed ID: 29124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.